Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2013 1
2016 4
2017 1
2018 2
2019 2
2021 3
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic implications of germline genetic findings in cancer.
Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, Ballinger ML, Thomas DM. Thavaneswaran S, et al. Nat Rev Clin Oncol. 2019 Jun;16(6):386-396. doi: 10.1038/s41571-019-0179-3. Nat Rev Clin Oncol. 2019. PMID: 30783251 Review.
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Zeverijn LJ, Looze EJ, Thavaneswaran S, van Berge Henegouwen JM, Simes RJ, Hoes LR, Sjoquist KM, van der Wijngaart H, Sebastian L, Geurts BS, Lee CK, de Wit GF, Espinoza D, Roepman P, Lin FP, Jansen AML, de Leng WWJ, van der Noort V, Leek LVM, de Vos FYFL, van Herpen CML, Gelderblom H, Verheul HMW, Thomas DM, Voest EE. Zeverijn LJ, et al. Among authors: thavaneswaran s. Int J Cancer. 2023 Oct 1;153(7):1413-1422. doi: 10.1002/ijc.34649. Epub 2023 Jul 10. Int J Cancer. 2023. PMID: 37424386 Clinical Trial.
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
Thavaneswaran S, Kansara M, Lin F, Espinoza D, Grady JP, Lee CK, Ballinger ML, Sebastian L, Corpuz T, Qiu MR, Mundra P, Bailey CG, Schmitz U, Simes J, Joshua AM, Thomas DM. Thavaneswaran S, et al. Br J Cancer. 2023 Aug;129(3):475-485. doi: 10.1038/s41416-023-02311-0. Epub 2023 Jun 26. Br J Cancer. 2023. PMID: 37365284 Free PMC article. Clinical Trial.
Optimal therapy for resectable rectal cancer.
Thavaneswaran S, Price TJ. Thavaneswaran S, et al. Expert Rev Anticancer Ther. 2016;16(3):285-302. doi: 10.1586/14737140.2016.1130627. Epub 2016 Jan 11. Expert Rev Anticancer Ther. 2016. PMID: 26652907 Review.
Malignant melanocytic schwannian tumor and leptomeningeal disease: A case series with a focus on management.
Woodford R, Prather L, Helfer C, Davey L, Penas-Prado M, Armstrong T, Tucker K, Aldape K, Gilbert M, Clark C, Thavaneswaran S, Wang D, Mandel J, Kasherman L. Woodford R, et al. Among authors: thavaneswaran s. J Neurol Sci. 2022 Jul 15;438:120291. doi: 10.1016/j.jns.2022.120291. Epub 2022 May 16. J Neurol Sci. 2022. PMID: 35635863 No abstract available.
Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion.
Thavaneswaran S, Chan WY, Asghari R, Grady JP, Deegan M, Jansen VM, Thomas DM. Thavaneswaran S, et al. JCO Precis Oncol. 2022 Nov;6:e2200263. doi: 10.1200/PO.22.00263. JCO Precis Oncol. 2022. PMID: 36455193 Free PMC article. No abstract available.
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.
Kansara M, Bhardwaj N, Thavaneswaran S, Xu C, Lee JK, Chang LB, Madison RW, Lin F, Hsu E, Patel VK, Aleshin A, Oxnard GR, Simes J, Nimeiri H, Thomas DM. Kansara M, et al. Among authors: thavaneswaran s. Mol Oncol. 2023 Feb;17(2):298-311. doi: 10.1002/1878-0261.13349. Epub 2022 Dec 13. Mol Oncol. 2023. PMID: 36426653 Free PMC article.
21 results